Metabolites of lorazepam

Relevance of past findings to present day use of LC-MS/MS in analytical toxicology

Sophie C. Turfus, Robin A. Braithwaite, David A. Cowan, Mark C. Parkin, Norman W. Smith, Andrew T. Kicman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The advent of liquid chromatography-tandem mass spectrometry (LC-MS/MS), with the sensitivity it confers, permits the analysis of both phase I and II drug metabolites that in the past would have been difficult to target using other techniques. These metabolites may have relevance to current analytical toxicology employing LC-MS/MS, and lorazepam was chosen as a model drug for investigation, as only the parent compound has been targeted for screening purposes. Following lorazepam administration (2 mg, p.o.) to 6 volunteers, metabolites were identified in urine by electrospray ionization LC-MS/MS, aided by the use of deuterated analogues generated by microsomal incubation for use as internal chromatographic and mass spectrometric markers. Metabolites present were lorazepam glucuronide, a quinazolinone, a quinazoline carboxylic acid, and two hydroxylorazepam isomers, one of which is novel, having the hydroxyl group located on the fused chlorobenzene ring. The quinazolinone, and particularly the quinazoline carboxylic acid metabolite, provided longer detection windows than lorazepam in urine extracts not subjected to enzymatic hydrolysis, a finding that is highly relevant to toxicology laboratories that omit hydrolysis in order to rapidly reduce the time spent on gas chromatography-mass spectrometry (GC-MS) analysis. With hydrolysis, the longest windows of detection were achieved by monitoring lorazepam, supporting the targeting of the aglycone with free drug for those incorporating hydrolysis in their analytical toxicology procedures.

Original languageEnglish
Pages (from-to)695-704
Number of pages10
JournalDrug Testing and Analysis
Volume3
Issue number10
DOIs
Publication statusPublished - 1 Oct 2011
Externally publishedYes

Fingerprint

Lorazepam
toxicology
Metabolites
Toxicology
metabolite
Hydrolysis
Quinazolinones
Quinazolines
hydrolysis
Carboxylic Acids
drug
carboxylic acid
urine
Urine
Pharmaceutical Preparations
Mass spectrometry
mass spectrometry
Tandem Mass Spectrometry
Electrospray ionization
chlorobenzene

Cite this

Turfus, Sophie C. ; Braithwaite, Robin A. ; Cowan, David A. ; Parkin, Mark C. ; Smith, Norman W. ; Kicman, Andrew T. / Metabolites of lorazepam : Relevance of past findings to present day use of LC-MS/MS in analytical toxicology. In: Drug Testing and Analysis. 2011 ; Vol. 3, No. 10. pp. 695-704.
@article{6e9c8b352cc64f93a2d1e58c7579fd24,
title = "Metabolites of lorazepam: Relevance of past findings to present day use of LC-MS/MS in analytical toxicology",
abstract = "The advent of liquid chromatography-tandem mass spectrometry (LC-MS/MS), with the sensitivity it confers, permits the analysis of both phase I and II drug metabolites that in the past would have been difficult to target using other techniques. These metabolites may have relevance to current analytical toxicology employing LC-MS/MS, and lorazepam was chosen as a model drug for investigation, as only the parent compound has been targeted for screening purposes. Following lorazepam administration (2 mg, p.o.) to 6 volunteers, metabolites were identified in urine by electrospray ionization LC-MS/MS, aided by the use of deuterated analogues generated by microsomal incubation for use as internal chromatographic and mass spectrometric markers. Metabolites present were lorazepam glucuronide, a quinazolinone, a quinazoline carboxylic acid, and two hydroxylorazepam isomers, one of which is novel, having the hydroxyl group located on the fused chlorobenzene ring. The quinazolinone, and particularly the quinazoline carboxylic acid metabolite, provided longer detection windows than lorazepam in urine extracts not subjected to enzymatic hydrolysis, a finding that is highly relevant to toxicology laboratories that omit hydrolysis in order to rapidly reduce the time spent on gas chromatography-mass spectrometry (GC-MS) analysis. With hydrolysis, the longest windows of detection were achieved by monitoring lorazepam, supporting the targeting of the aglycone with free drug for those incorporating hydrolysis in their analytical toxicology procedures.",
keywords = "Analytical toxicology, Benzodiazepines, Drug metabolism, Forensic, LC-MS/MS, Lorazepam",
author = "Turfus, {Sophie C.} and Braithwaite, {Robin A.} and Cowan, {David A.} and Parkin, {Mark C.} and Smith, {Norman W.} and Kicman, {Andrew T.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1002/dta.305",
language = "English",
volume = "3",
pages = "695--704",
journal = "Drug Testing and Analysis",
issn = "1942-7603",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

Metabolites of lorazepam : Relevance of past findings to present day use of LC-MS/MS in analytical toxicology. / Turfus, Sophie C.; Braithwaite, Robin A.; Cowan, David A.; Parkin, Mark C.; Smith, Norman W.; Kicman, Andrew T.

In: Drug Testing and Analysis, Vol. 3, No. 10, 01.10.2011, p. 695-704.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Metabolites of lorazepam

T2 - Relevance of past findings to present day use of LC-MS/MS in analytical toxicology

AU - Turfus, Sophie C.

AU - Braithwaite, Robin A.

AU - Cowan, David A.

AU - Parkin, Mark C.

AU - Smith, Norman W.

AU - Kicman, Andrew T.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - The advent of liquid chromatography-tandem mass spectrometry (LC-MS/MS), with the sensitivity it confers, permits the analysis of both phase I and II drug metabolites that in the past would have been difficult to target using other techniques. These metabolites may have relevance to current analytical toxicology employing LC-MS/MS, and lorazepam was chosen as a model drug for investigation, as only the parent compound has been targeted for screening purposes. Following lorazepam administration (2 mg, p.o.) to 6 volunteers, metabolites were identified in urine by electrospray ionization LC-MS/MS, aided by the use of deuterated analogues generated by microsomal incubation for use as internal chromatographic and mass spectrometric markers. Metabolites present were lorazepam glucuronide, a quinazolinone, a quinazoline carboxylic acid, and two hydroxylorazepam isomers, one of which is novel, having the hydroxyl group located on the fused chlorobenzene ring. The quinazolinone, and particularly the quinazoline carboxylic acid metabolite, provided longer detection windows than lorazepam in urine extracts not subjected to enzymatic hydrolysis, a finding that is highly relevant to toxicology laboratories that omit hydrolysis in order to rapidly reduce the time spent on gas chromatography-mass spectrometry (GC-MS) analysis. With hydrolysis, the longest windows of detection were achieved by monitoring lorazepam, supporting the targeting of the aglycone with free drug for those incorporating hydrolysis in their analytical toxicology procedures.

AB - The advent of liquid chromatography-tandem mass spectrometry (LC-MS/MS), with the sensitivity it confers, permits the analysis of both phase I and II drug metabolites that in the past would have been difficult to target using other techniques. These metabolites may have relevance to current analytical toxicology employing LC-MS/MS, and lorazepam was chosen as a model drug for investigation, as only the parent compound has been targeted for screening purposes. Following lorazepam administration (2 mg, p.o.) to 6 volunteers, metabolites were identified in urine by electrospray ionization LC-MS/MS, aided by the use of deuterated analogues generated by microsomal incubation for use as internal chromatographic and mass spectrometric markers. Metabolites present were lorazepam glucuronide, a quinazolinone, a quinazoline carboxylic acid, and two hydroxylorazepam isomers, one of which is novel, having the hydroxyl group located on the fused chlorobenzene ring. The quinazolinone, and particularly the quinazoline carboxylic acid metabolite, provided longer detection windows than lorazepam in urine extracts not subjected to enzymatic hydrolysis, a finding that is highly relevant to toxicology laboratories that omit hydrolysis in order to rapidly reduce the time spent on gas chromatography-mass spectrometry (GC-MS) analysis. With hydrolysis, the longest windows of detection were achieved by monitoring lorazepam, supporting the targeting of the aglycone with free drug for those incorporating hydrolysis in their analytical toxicology procedures.

KW - Analytical toxicology

KW - Benzodiazepines

KW - Drug metabolism

KW - Forensic

KW - LC-MS/MS

KW - Lorazepam

UR - http://www.scopus.com/inward/record.url?scp=84857086999&partnerID=8YFLogxK

U2 - 10.1002/dta.305

DO - 10.1002/dta.305

M3 - Article

VL - 3

SP - 695

EP - 704

JO - Drug Testing and Analysis

JF - Drug Testing and Analysis

SN - 1942-7603

IS - 10

ER -